Highlight

1.Clear MOA

1) GLP-1 is a hypoglycemic agent. By activating GLP-1 receptor, it enhances insulin secretion in a glucose-concentration-dependent manner, inhibits glucagon secretion, delays gastric emptying, and reduces food intake through central appetite inhibition, thus reducing blood sugar, Weight loss and other effects.

2) GIP secreted by K cells of duodenal mucosa are hormones produced by the digestive tract to control food intake and many metabolic processes. When glucose is ingested, these hormones will initially cause increased insulin release and subsequently lead to decreased blood sugar. It can also affect appetite regulation and fat metabolism.

2. Molecular design:

By moderately increased GCG activity and GIP activity gives this asset a glucose-lowering and weight-loss ability that exceeds semaglutide, meanwhile, it was better than Tirzepatide in lowering cholesterol and other indicators.

3. Manufacture process:

High expression and purity in CHO cell line, give this asset unique advantage of lower cost.

4. In vivo result

1) Significantly improved fasting blood glucose and postprandial blood glucose of diabetic rhesus monkeys, and the hypoglycemic effect was similar to that of semaglutide.

2) Significantly reduced the insulin resistance and increased the rate of glucose uptake, the effect was similar to that of semaglutide.

3) Significantly improve the body weight of obese rhesus monkeys, and the effect of weight reduction was similar to that of semaglutide.

4) Significantly decreased body fat of obese rhesus monkeys and LDL, the effect was better than that of semaglutide.